An experimental study has been performed to compare the in vitro activity and the in vivo efficacy of tachyplesin III, colistin and imipenem against multiresistant Pseudomonas aeruginosa strain. In vitro experiments included MIC determination, time-kill and synergy studies. For in vivo studies, a mouse model of sepsis has been used. Main outcome measures were: lethality, quantitative blood cultures and detection of LPS, TNF-alpha and interleukin-6 (IL-6) plasma levels.
Introduction
Resistance among bacteria is on the rise, both in the hospital and in the community (3, 22) . In comparison with gram-positive cocci, for which resistance to a single antibiotic indicates the antibiotic resistance phenotype of interest, multidrug resistance in gram-negative bacilli is difficult to define. Among these resistant bacteria, Pseudomonas aeruginosa represent a pathogen with notable virulence characteristics and the ability to exhibit antibiotic resistance. Multidrug resistance in P. aeruginosa has been variously defined as resistance to at least 2 or more antibiotics typically used to treat infections with these organisms. These definitions are clearly arbitrary and may be of questionable practical value to a clinician (21,23). Of greater relevance may be a definition of "panresistance," because the complete or almost complete lack of treatment options beta-lactams, carbapenem and fluoroquinolones is an increasingly common and desperate occurrence in hospital setting (23).
Antimicrobial therapy for infections due to these multi-resistant organisms remains a clinical dilemma in hospitalized patients. Strategies for prevention and therapy, include both infection control and modifications in antibiotic use such as antibiotic cycling or rotation, combination therapies and the use of "old" and new drugs for the management of infections with gram-negative bacilli resistant to all other alternatives (4, 17) .
After the discovery of polymyxins, a number of cationic peptides have been isolated from a wide range of bacterial species, plant and animals (2, 13, 15) . They are a recently emerged class of antibiotics with therapeutic potential. These molecules are important components of the innate immune response in most multi-cellular organisms used by animals to effectively deal with pathogenic microorganisms in their environmentions (13, 15, 19) . In mammals, peptides are found in circulating phagocytes, where they contribute to the killing of engulfed micro organisms, and in
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Tachyplesins are a group of antimicrobial peptides isolated from horseshoe crabs. Tachyplesin III (KWCFRVCYRGICYRKCR-NH 2 ) isolated from Southeast Asian horseshoe crabs Tachypleus gigas and Carcinoscorpius rotundicauda, hem lymph consisting of 17 amino acids with two disulfide bridges is a representative antimicrobial peptide with cyclic β-sheet. It is similar in structure and activity profile to protegrins, a family of peptides found in pig intestines. Because of its potency and relatively small sizes, this peptide is an attractive target for structure-activity studies that may lead to therapeutics to treat infections (14, 20) . Tachyplesin III exhibit a broad-spectrum activity against gram-negative and -positive bacteria, fungi and even enveloped viruses at low concentrations. Furthermore, it has also been shown to play a role in the proinflammatory response because it forms complexes with bacterial lipopolysaccharides that neutralize the factor C-activating activity of LPS in a manner similar to that of anti-LPS factor (20) . It was reported, even though the precise action mechanism of the cationic peptides remains to be determined, that they rapidly perturbed the membrane function of pathogenic microorganisms Recent reports have shown that synergistic effect was observed in several clinically isolated bacterial strains when some antimicrobial peptides were combined with several clinically used antibiotics. Therefore, the presence of this synergistic effect makes the cationic peptides potentially valuable as an adjuvant for antimicrobial chemotherapy against antibiotic-resistant bacterial strains (10, 25) .
In order to broaden our knowledge of this role, we evaluated the activity of the combination of tachyplesin III, colistin and imipenem in vitro and in vivo using two P. aeruginosa strains. 
Materials and Methods
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Synthetic peptide
Tachyplesin III (molecular weight 2495,5 Da) was synthesized by 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase chemistry (5, 9) . The protected peptidyl resin was treated with the mixture: 92% trifluoroacetic acid (TFA), 2% ethanedithiol (EDT), 2% water and 2% triisopropylosilane (TIS) for 2 h. After cleavage the solid support was removed by filtration, and the filtrate was concentrated under reduced pressure. The cleaved peptide was precipitated with diethyl ether, dissolved in 20% acetic acid and oxidized by 0.1 M iodine in methanol. Tachyplesin III was purified and analyzed by high-performance liquid chromatography (HPLC). The resulting fractions with purity greater than 94-95% were tested by HPLC. The peptide was analyzed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF). The peptide was solubilized in phosphate buffered saline (pH 7.2) yielding 1 mg/ml stock solution. Solutions of drugs were made fresh on the day of assay or stored at -80°C in the dark for short periods.
MIC determination and bacterial killing assay
Tachyplesin III, colistin (Sigma-Aldrich, Milan, Italy) and imipenem (Merck, Sharp & Dohme, Milan, Italy), powders were diluted in accordance with manufacturers' recommendations. Solutions of drugs were made fresh on the day of assay or stored at -80°C in the dark until twenty days. The the effects of the combination were considered to be additive. 
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Synergy studies
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Hemolysis of human red blood cells and cytotoxicity assay
Fresh hRBC with EDTA were rinsed 3 times with PBS (35 mM phosphate buffer/0.15 M NaCl, pH 
Preparation and implantation of the inoculum and antibiotic therapy
P. aeruginosa ATCC 27853 and clinical isolate strain were grown overnight at 37°C in brain-heart infusion broth. When bacteria were in the log phase of growth the suspension was centrifuged at 1000 x g for 15 min, the supernatant was discarded, and the bacteria were resuspended in sterile saline to achieve a concentration of approximately 1×10 8 CFU/mL. All animals were anesthetized by an intramuscular injection of ketamine (30 mg/kg of body weight). Mice were injected intravenously (i.v.) via the tail vein with 0.2 mL of the above mentioned bacterial suspensions: i)
2.0×10 7 cfu of strains on day 0 and monitored for 72 hours.
Immediately after bacterial challenge, the mice were randomized to receive intravenously isotonic IL-6 and TNF-alpha levels were measured by ELISA according to the manufacturer's specification (Walter Occhiena srl, Turin, Italy). The lower limits of sensitivity for IL-6 and TNF-alpha were 12 pg/ml and 0.05 ng/ml, respectively. The assays were performed in duplicate.
Statistical analysis
Lethality rates between groups were compared by use of Fisher's exact test. Data from quantitative blood cultures were presented as means ± standard deviations (SDs) of the mean; statistical comparisons between groups were made by analysis of variance. Post hoc comparisons were performed by Bonferroni's test. Plasma endotoxin, IL-6 and TNF-alpha mean values were compared between groups by analysis of variance. Significance was accepted when the p value was ≤0.05. The cytotoxic effect was practically absent at the concentrations tested. Finally our data revealed that the peptide showed low haemolytic activity in spite of their high activity against the organism. In fact, its haemolytic activity was observed at concentrations higher than MIC values (4.5%, 12.6%, and 26,7% at concentrations of 8, 16, and 32 mg/L, respectively).
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In vivo studies
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As shown in Table 1 , control group C 1 , showed a 100% lethality rate within 72 hours. In contrast, for both the strains, immediate treatment with drugs demonstrated efficacy significantly higher than controls (P <0.05). For P. aeruginosa ATCC 27853 lethality rates of 30%, 30%, and 40% were observed for groups treated with imipenem, tachyplesin III and colistin A, respectively. For the clinical strain, imipenem showed an higher lethality rate (80%) while the same lethality rates were observed for peptide-treated groups (30%). The combination between tachyplesin III or colistin and imipenem showed significantly lowest lethality rates of 5% and 10% for the control strain and 10, and 15% for the clinical isolate, respectively. Quantitative blood culture showed high bacterial numbers both in the ATCC 27853 group (5.8 × 10 7 ± 0.8 × 10 7 CFU/ml) and in the clinical isolate group (7.9 × 10 7 ± 2.2 × 10 7 cfu/mL), as shown in Table 1 . Tachyplesin III demonstrated a good antibacterial activity against ATCC strain reducing the bacterial growth to 3.6 × 10 3 ± 0.6 × 10 3 cfu/mL, comparable to those of colistin and imipenem (6.0 × 10 4 ± 1.7 × 10 4 cfu/mL and 2.8 × 10 3 ± 0.4 × 10 3 cfu/mL, respectively). When imipenem was combined with tachyplesin III and colistin, the positive interactions produced the lowest bacterial counts (1.1 × 10 1 ± 0.1 × 10 1 cfu/mL for tachyplesin III plus imipenem and 4.6 × 10 1 ± 0.5 × 10 1 for colistin plus imipenem). Against the panresistant strain tachyplesin III and colistin showed antibacterial activity comparable to that against the ATCC strain, while imipenem showed weak activity. Similarly to the previous experiment, when imipenem was combined with tachyplesin III and colistin the positive interaction produced the lowest bacterial counts. Overall, any combined-treated group had significant lower bacterial counts when compared to singly-treated groups (P <0.05).
For both the strains, plasma peak levels of endotoxin, TNF-alpha and IL-6 were observed 6 and 12 h after bacterial challenge, respectively. tachyplesin III and colistin treatments (alone or combined) resulted in marked decrease (P <0.05) of endotoxin, TNF-alpha and IL-6 plasma levels compared with those of controls and vancomycin-treated groups. (Figure 1-3) . The strongest reduction in None of the animals had clinical evidence of drug-related adverse effects, hypersensitivity reactions, and no changes in physiological parameters were observed in the supplementary peptides-treated groups without previous infection.
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Discussion
It is well known that P. aeruginosa may become resistant to the antibiotic being used to treat the infection and that prior use of a particular antibiotic predicts that P. aeruginosa will develop resistance to that antibiotic. The main reasons for this bacterial resistance is thought to be the organism's low outer membrane permeability to antimicrobial agents, genetic elements capable to carry and transfer diverse antibiotic resistance determinants and, finally, efflux pumps. Due to its potent inflammatory activity and association with sepsis, LPS can be an important virulence factor in Pseudomonas infections (1, 12) .
In the present study, we evaluated the efficacy of the combination between tachyplesin, colistin and imipenem two strains of P. aeruginosa with different pattern of susceptibility, first in vitro and then in vivo. We used one susceptible and one multiresistant strain that can be been associated with clinical failure following antibiotic therapy. In time-killing curves and in checkerboard titration method, a synergistic effect between the peptides and imipenem was observed. This synergistic pattern clearly was also observed in the in vivo setting. Previous studies have reported contradictory results about the interaction among peptides and antibiotics (7, 10, 25, 26) . The peptide acts by inserting into the cytoplasmic membrane and triggering the activity of bacterial murein hydrolases, resulting in damage or degradation of bacterial membranes, and lysis of the cell. In addition, antimicrobial peptides can induce, by the loss of effective outer
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As it has been described previously, a sepsis mouse model was able to compare the efficacy among different antibiotic therapies and also the efficacy of a therapy among strains with different susceptibilities. We selected as main outcome measures lethality, quantitative blood cultures and detection of endotoxin, TNF-alpha and IL-6 plasma levels to have different parameters and better define the efficacies of the treatments. We used a short period of treatment of 24 h in order to increase the relevance of the model, since this is the critical period of such an acute infection (16).
In our model, tachyplesin III and colistin showed superior (clinical isolate) or similar (ATCC control strain) antimicrobial activities and comparable lethality rates to those of imipenem.
Differently, they demonstrated an higher ability to inhibit the effects of endotoxin and, consequently, the release of cytokines than imipenem.
Finally, the best results on mortality rates and bacteremia were obtained when tachyplesin 
